Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 115,097,456
  • Shares Outstanding, K 735,400
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.28
  • Price/Sales 5.05
  • Price/Cash Flow 10.79
  • Price/Book 3.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
152.45 +0.37%
on 05/22/17
165.61 -7.60%
on 04/26/17
-7.39 (-4.61%)
since 04/21/17
3-Month
152.45 +0.37%
on 05/22/17
184.21 -16.93%
on 03/15/17
-19.59 (-11.35%)
since 02/22/17
52-Week
133.64 +14.50%
on 11/04/16
184.21 -16.93%
on 03/15/17
+2.84 (+1.89%)
since 05/20/16

Most Recent Stories

More News
Asian shares drift as blast in Manchester rattles investors

TOKYO (AP) — Asian shares were mostly higher in early trading Tuesday after police said they were treating an explosion in Manchester, England, that killed at least 19 people as a terror attack. Oil...

HUN : 26.15 (-2.10%)
LMT : 277.03 (+1.55%)
CSCO : 31.59 (+1.22%)
F : 11.10 (+2.12%)
AMGN : 153.02 (-2.23%)
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Amgen Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (Nasdaq: AMGN)....

AMGN : 153.02 (-2.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN

Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMGN : 153.02 (-2.23%)
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

AZN : 33.95 (+0.15%)
VVUS : 1.08 (+3.85%)
AMGN : 153.02 (-2.23%)
VRX : 13.45 (-0.52%)
Amgen Falls 2.15% on Heavy Volume: Watch For Potential Rebound

Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.66 to a high of $154.60. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $156.29 on...

AMGN : 153.02 (-2.23%)
Amgen Evenity Approval Derailed on Cardiovascular Side Effect

A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.

AKTX : 7.64 (+5.09%)
VVUS : 1.08 (+3.85%)
MRK : 64.04 (+0.41%)
AMGN : 153.02 (-2.23%)
George Bennett Rides to Victory in Pasadena at the 2017 Amgen Tour of California

After cycling for seven days and 583 miles across California, Team LottoNL-Jumbo's George Bennett (NZL) claimed the 2017 Amgen Tour of California race championship today in Pasadena with...

AMGN : 153.02 (-2.23%)
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

AGN : 219.52 (+0.18%)
NVS : 81.29 (+1.08%)
TEVA : 29.44 (-1.47%)
AMGN : 153.02 (-2.23%)
Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications

Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.

MRK : 64.04 (+0.41%)
AMGN : 153.02 (-2.23%)
PFE : 32.12 (-1.05%)
GSK : 43.30 (-0.69%)
AbbVie Down on Humira Patent Loss: Is More Damage in Store?

AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc....

AGN : 219.52 (+0.18%)
CHRS : 21.10 (-5.38%)
ABBV : 65.44 (-0.21%)
AMGN : 153.02 (-2.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 155.51
1st Resistance Point 154.26
Last Price 153.02
1st Support Level 152.11
2nd Support Level 151.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.